CRSP
Price
$32.66
Change
-$1.53 (-4.47%)
Updated
Apr 3 closing price
Capitalization
2.93B
38 days until earnings call
YMAB
Price
$4.66
Change
-$0.14 (-2.92%)
Updated
Apr 3 closing price
Capitalization
210.94M
38 days until earnings call
Ad is loading...

CRSP vs YMAB

Header iconCRSP vs YMAB Comparison
Open Charts CRSP vs YMABBanner chart's image
CRISPR Therapeutics AG
Price$32.66
Change-$1.53 (-4.47%)
Volume$2.12M
Capitalization2.93B
Y-mAbs Therapeutics
Price$4.66
Change-$0.14 (-2.92%)
Volume$822.66K
Capitalization210.94M
CRSP vs YMAB Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. YMAB commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and YMAB is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (CRSP: $32.66 vs. YMAB: $4.66)
Brand notoriety: CRSP and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 98% vs. YMAB: 192%
Market capitalization -- CRSP: $2.93B vs. YMAB: $210.94M
CRSP [@Biotechnology] is valued at $2.93B. YMAB’s [@Biotechnology] market capitalization is $210.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileYMAB’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • YMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, YMAB is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish while YMAB’s TA Score has 5 bullish TA indicator(s).

  • CRSP’s TA Score: 4 bullish, 6 bearish.
  • YMAB’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, YMAB is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а -14.14% price change this week, while YMAB (@Biotechnology) price change was -6.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

CRSP is expected to report earnings on May 12, 2025.

YMAB is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($2.93B) has a higher market cap than YMAB($211M). CRSP YTD gains are higher at: -17.022 vs. YMAB (-40.485). YMAB has higher annual earnings (EBITDA): -30.67M vs. CRSP (-447.31M). CRSP has more cash in the bank: 1.9B vs. YMAB (67.2M). YMAB has less debt than CRSP: YMAB (820K) vs CRSP (224M). YMAB has higher revenues than CRSP: YMAB (87.7M) vs CRSP (35M).
CRSPYMABCRSP / YMAB
Capitalization2.93B211M1,390%
EBITDA-447.31M-30.67M1,459%
Gain YTD-17.022-40.48542%
P/E RatioN/AN/A-
Revenue35M87.7M40%
Total Cash1.9B67.2M2,833%
Total Debt224M820K27,317%
FUNDAMENTALS RATINGS
CRSP vs YMAB: Fundamental Ratings
CRSP
YMAB
OUTLOOK RATING
1..100
589
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9496
PRICE GROWTH RATING
1..100
8894
P/E GROWTH RATING
1..100
76100
SEASONALITY SCORE
1..100
4885

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

YMAB's Valuation (39) in the Pharmaceuticals Major industry is in the same range as CRSP (67) in the Biotechnology industry. This means that YMAB’s stock grew similarly to CRSP’s over the last 12 months.

YMAB's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CRSP (100) in the Biotechnology industry. This means that YMAB’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as YMAB (96) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to YMAB’s over the last 12 months.

CRSP's Price Growth Rating (88) in the Biotechnology industry is in the same range as YMAB (94) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to YMAB’s over the last 12 months.

CRSP's P/E Growth Rating (76) in the Biotechnology industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to YMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPYMAB
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MEMRX30.33N/A
N/A
MFS Emerging Markets Equity R1
RYFAX84.49N/A
N/A
Rydex Financial Services H
BCSCX8.59N/A
N/A
BlackRock Commodity Strategies Inv C
HDQVX16.26N/A
N/A
Janus Henderson Responsible Intl DivS
MAIFX9.16N/A
N/A
MoA International Fund